
Certara (CERT) Stock Forecast & Price Target
Certara (CERT) Analyst Ratings
Bulls say
Certara Inc's revenue composition indicates a robust growth trajectory, with services accounting for 66% of its revenue, although the overall services growth rate faced a slowdown in 2022 due to regulatory pressures. However, the acquisition of Pinnacle 21 has positively impacted the company's software revenue, contributing approximately 10% of total revenue and 25% of software revenue in FY23, and this segment is expected to grow above the corporate average. The ongoing secular growth in the biosimulation market is anticipated to drive demand for Certara's innovative solutions, which deliver significant time and cost savings in drug discovery and development processes.
Bears say
Certara Inc faces significant challenges that could negatively impact its financial outlook. A potential shift back toward services could hinder gross margin expansion, as service contributions are expected to drag on overall profitability despite an assumed gross margin of 60%+. Additionally, while the regulatory environment has historically been favorable, ongoing requirements for regulatory acceptance of new use cases may limit future growth opportunities for the company's biosimulation technologies.
This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.
Certara (CERT) Analyst Forecast & Price Prediction
Start investing in Certara (CERT)
Order type
Buy in
Order amount
Est. shares
0 shares